REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings ...

T he market expects Regenxbio (RGNX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 ...

Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The company’s shares closed yesterday at $7.00. Easily identify ...

Regenxbio (RGNX) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago. These figures are ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based company said ...

Regenxbio Inc (RGNX) showcases robust financial positioning and strategic progress in gene therapy, despite challenges in cash reserves and competitive landscapes.